NEXT-GENERATION RADIOIMMUNOTHERAPIES FOR NON-HODGKIN’S LYMPHOMA PATIENTS DECEMBER 2019 Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: [email protected] Forward-looking statements This slide presentation contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.This presentation is for information purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by the Company. The information and opinions in this presentation is provided as at the date hereof and subject to change without notice. It is not the intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company’s financial or trading position or prospects. This presentation does not constitute investment, legal, accounting, regulatory, taxation or other advice and does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs. You are solely responsible for forming your own opinions and conclusions on such matters and for making your own independent assessment of the Company. You are solely responsible for seeking independent professional advice in relation to the Company. No responsibility or liability is accepted by any person for any of the information or for any action taken by you or any of your officers, employees, agents or associates on the basis of such information. 2 Corporate snapshot Nordic Nanovector is a clinical-stage biopharmaceutical company dedicated to extending and improving the lives of patients with haematological cancers through the development and commercialisation of innovative targeted radioimmunotherapies • Founded 2009 in Oslo, Norway to develop • HQ and R&D in Oslo, with corporate offices Betalutin® for the treatment of non-Hodgkin’s in London, UK and Zug, Switzerland lymphoma (NHL) based on • 46 Employees (around 65 FTEs in total) – A spin-off of the Norwegian Radium Hospital, a centre of excellence for oncology biomedical • Listed on the Oslo Stock Exchange since research and patient care 2015 (NANO) – R&D expertise in radioimmunotherapies • Market cap USD 180M* 3 *As of November 29, 2019. Exchange rate 1 USD = 9.22113 NOK Management Team with international experience EDUARDO BRAVO TONE KVÅLE Chief Executive Officer Chief Financial Officer LISA ROJKJAER, MD JOSTEIN DAHLE, PhD Chief Medical Officer Co-Founder, Chief Scientific Officer MARCO RENOLDI, MD RITA DEGE Chief Operating Officer Chief Human Resources Officer ROSEMARIE CORRIGAN MALENE BRONDBERG Chief Quality Officer Vice President, IR & Corporate Communications GABRIELE ELBL LARS NIEBA Vice President Global Chief Technology Officer Regulatory Affairs 4 Nordic Nanovector – experts in radioimmunotherapy Fully owned lead asset – a novel anti-CD37 radioimmunotherapy targeting unmet needs in the two largest NHL types – FL and DLBCL – a near USD 5B* opportunity ® Betalutin A single administration of Betalutin® has demonstrated promising efficacy and safety in a 74-patient trial Pivotal trial in 3L R/R FL underway with full enrolment expected 2H 2020; Orphan Drug designation granted in EU and US, Fast Track designation On-going clinical programmes to access higher-value 2L FL and R/R DLBCL provide additional near-term value inflection points R&D expertise and IP provides multiple opportunities in B-cell malignancies FL – Follicular lymphoma; DLBCL – Diffuse large B-cell lymphoma: R/R – relapsed/refractory; 3L – 3rd line; 2L – 2nd line 5 * Pharmacor Oncology: Non Hodgkin’s Lymphoma by Decision Resources Group, 2015 Nordic Nanovector pipeline – Multiple attractive opportunities in NHL Candidate Targeted indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Betalutin® 3L FL PARADIGME – Pivotal Phase 2b Betalutin® 2L FL Archer-1 – Phase 1b (combination w/RTX) Betalutin® R/R DLBCL (SCT ineligible) LYMRIT 37-05 – Phase 1 Alpha37 (212Pb-NNV003)* CLL and other NHL INDR&D-ready Humalutin®** NHL IND-ready RTX – rituximab; DLBCL – diffuse large B-cell lymphoma: SCT – Stem cell transplant; ADC: antibody-drug conjugate; CLL: chronic lymphocytic leukaemia 6 *R&D collaboration **On hold, refocusing resources towards PARADIGME; Strategy to capture significant value in NHL 1 Clinical Development Goal: develop differentiated target product profile to meet requirements of regulatory 2 and reimbursement agencies Commercialisation Single-agent Betalutin® 3L R/R FL Goal: capture value of Betalutin® in the US; First-to-market indication the largest single market FL c.$2.1B ® Betalutin + RTX Refine US commercial strategy and deploy Accelerate access to 2L FL 2L R/R FL launch readiness plan through confirmatory Phase 3 trial Identify opportunities for ex-US regions Betalutin® DLBCL R/R DLBCL To maximize NHL opportunity in c.$2.7B largest NHL type 3 Platform Pipeline Development Goal: leverage expertise and IP to create long-term value internally and through strategic partnerships The slide shows the overall market potential in G7* – Source; Pharmacor Oncology: Non-Hodgkin’s Lymphoma, by Decision Resources Group, 2015 7 *Germany, France, Italy, Spain, United Kingdom, United States, Japan NHL – HIGH UNMET NEED DESPITE AVAILABLE TREATMENTS Nordic Nanovector ASA Kjelsåsveien 168 B, 0884 Oslo, Norway www.nordicnanovector.com IR contact: [email protected] NHL – high unmet need despite available treatments NHL • 7th most common cancer in the US1 • Median age at diagnosis is 67 years1 85% 15% • Incidence across G7* is 17 per 100,000 per year, B-cell NHL T-cell NHL resulting in >130,200 new cases in 20142 • Expected to grow by nearly 20% by 2024, as a result of population growth and aging population2 • Market potential expected to reach $28.7 billion by Indolent (iNHL) Aggressive (40% of all NHL) (60% of all NHL) 20263 • FL (~20%) • DLBCL (~40%) • Marginal zone lymphoma (MZL) • Burkitt lymphoma • Lymphoplasmacytic lymphoma • Lymphoblastic lymphoma • Chronic lymphocytic leukemia/small- • Mantle cell lymphoma cell lymphocytic lymphoma (CLL/SLL) • Primary mediastinal large B-cell lymphoma 1seer.cancer.gov 2Pharmacor Oncology: Non-Hodgkin’s Lymphoma, by Decision Resources Group, 2015 3Landscape & Forecast: Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia, by Decision Resources Group, 2017 9 * France, Germany, Italy, Spain, United Kingdom, United States, Japan FL - shorter remissions with each successive therapy and no cure at present 1st line 2nd line 3rd line Later lines Approx. 24,000 patients Approx. 16,000 patients Approx. 10,000 patients Approx. 5,000 patients Idelalisib Anti-CD20 Anti-CD20 Clinical trials with novel drugs (Rituximab, obinutuzumab) (Rituximab, obinutuzumab) (CAR-T) + OR + Chemotherapy BSC / Palliative therapy Chemotherapy (Bendamustine, fludarabine, CHOP) Copanlisib (Bendamustine, CHOP, CVP) OR OR Anti-CD20 Duvelisib Followed by: (Rituximab) • Rituximab maintenance + OR Immunomodulatory agents • Radioimmunotherapy Rituximab (Lenalidomide) OR OR Radioimmunotherapy Radioimmunotherapy Followed by: • High dose chemo + Stem Cell Transplant • Allogenic SCT • Rituximab / obinutuzumab maintenance Treatment regimens including listed options are either approved or recommended by NCCN or ESMO guidelines Remission Remission Remission Remission Remission 10 Relapse Relapse Relapse Relapse DLBCL – limited treatment options for patients relapsing after first-line therapy 1st line 2nd line 3rd line Approx. 46,000 patients Approx. 18,000 patients Approx. 10,000 patients Anti-CD20 High-dose (Rituximab) 30-40% Y immunochemotherapy (R- Abicabtagene ciloleucel + DHAP, R-ESHAP, R-GDP, R- OR Chemotherapy GemOx. R-ICE)